Allergan has reported revenues from continuing operations up by 48 percent to $3.8 billion for the quarter ended March 31, 2016, as compared to the first quarter of 2015. The strong performance was primarily driven by global sales of branded products and sales of top global products within the U.S. Brands, U.S. Medical and International Brands segments. Adjusted Ebitda from continuing operations jumped by 65 percent to $1.8 billion.

Total global branded product revenues were $3.4 billion, up from $2.0 billion in the prior year quarter. U.S. Brands revenues of $2.3 billion for the first quarter represented a 27 percent increase over the first quarter of 2015. U.S. Brands growth was mainly attributed to the acquisition of legacy Allergan products, including Botox and Restasis, as well as the launch of the new products Avycaz, Dalvance and Liletta. Allergan's U.S. eyecare brands generated $533 million in revenues during the quarter.